European research project examines toxicity factor to fight AIDS

December 1st is the annual World AIDS Day, a perfect opportunity to look at how medical research is progressing to fight the disease.

HIV is still plaguing humanity with 35 million infected people worldwide. Antiretroviral drugs do slow down the progression of the disease but at a high cost and with long term toxicity. More than ever, the need for a vaccine is stringent.

At the heart of a current European research project, the idea is to block the entry of HIV into cells, both at mucosal sites and in blood. Why target mucosal sites? Because 90% of HIV infections happen via the sexual route. Obtaining an immune response at this gateway could therefore mean efficiently blocking the virus and prevent it from ever entering the body.

A first clinical trial on humans has just finished to check for toxicity. In a next step, researcher will then determine whether the blood and mucosal tissue of the volunteers will produce the neutralizing antibodies, once confronted to HIV in the lab.

Watch video: http://www.youris.com/Health/HEALTHTV/New_Hopes_For_An_AIDS_Vaccine.kl#ixzz2llnnTljb

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research shows brain synchronization between humans and dogs